Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut.

نویسندگان

  • Grace Lu-Yao
  • Peter C Albertsen
  • Janet L Stanford
  • Therese A Stukel
  • Elizabeth S Walker-Corkery
  • Michael J Barry
چکیده

OBJECTIVE To determine whether the more intensive screening and treatment for prostate cancer in the Seattle-Puget Sound area in 1987-90 led to lower mortality from prostate cancer than in Connecticut. DESIGN Natural experiment comparing two fixed cohorts from 1987 to 1997. SETTING Seattle-Puget Sound and Connecticut surveillance, epidemiology, and end results areas. PARTICIPANTS Population based cohorts of male Medicare beneficiaries aged 65-79 drawn from the Seattle (n=94 900) and Connecticut (n=120 621) areas. MAIN OUTCOME MEASURES Rates of screening for prostate cancer, treatment with radical prostatectomy and external beam radiotherapy, and prostate cancer specific mortality. RESULTS The prostate specific antigen testing rate in Seattle was 5.39 (95% confidence interval 4.76 to 6.11) times that of Connecticut, and the prostate biopsy rate was 2.20 (1.81 to 2.68) times that of Connecticut during 1987-90. The 10 year cumulative incidences of radical prostatectomy and external beam radiotherapy up to 1996 were 2.7% and 3.9% for Seattle cohort members compared with 0.5% and 3.1% for Connecticut cohort members. The adjusted rate ratio of prostate cancer mortality up to 1997 was 1.03 (0.95 to 1.11) in Seattle compared with Connecticut. CONCLUSION More intensive screening for prostate cancer and treatment with radical prostatectomy and external beam radiotherapy among Medicare beneficiaries in the Seattle area than in the Connecticut area was not associated with lower prostate cancer specific mortality over 11 years of follow up.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Treating violence as a public health problem.

1 Giddens A. Modernity and self-identity. Cambridge: Polity, 1991. 2 Dixon-Woods M, Baum M, Kurinczuk JJ. Screening for breast cancer with mammography Lancet 358:2166-7. 3 Ciatto S, Zappa R, Bonardi G, Gervasi G. Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast screening. Eur J Cancer 2000;36:1347-50. 4 NHS Cancer Screening Programmes. The prostate c...

متن کامل

PSA Screening in Prostate Cancer

Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...

متن کامل

بررسی نقش بیومارکری ژن ها در تمیز دادن نمونه های سرطانی متاستازی و اولیه از بافت نرمال در سرطان پروستات

Background & Aims: Prostate cancer (PCa) is the second most common cancer in men worldwide. The identification of sensitive and specific biomarkers in tissue and serum is of utmost importance to reduce the mortality of prostate cancer. Since that, early detection of cancer has an important role in treatment, in this study we tried to identify genes that could potentially effective in early...

متن کامل

Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower

ONE OF THE MOST COMMON cancer screening activities in the United States is the measurement of prostatespecific antigen (PSA) levels for the early detection of prostate cancer. In 2001, approximately 75% of men in the United States aged 50 years and older reported that they had previously undergone PSA screening and 54% have reported regular PSA screening. Prostate cancer screening with PSA has ...

متن کامل

Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening

Background: Prostate cancer is the second form of cancer among men worldwide. For early cancer detection, we should identify tumors in initial stages before the physical signs become visible. The present study aims to evaluate the diagnostic value of cell-free DNA (cfDNA), its comparison with prostate-specific antigen (PSA) level in prostate cancer screening and also in patients with localized ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • BMJ

دوره 325 7367  شماره 

صفحات  -

تاریخ انتشار 2002